Draft FDA guidance could be a boon for gene therapy developers
Source: SeekingAlpha
2026-06-02 13:50:48 ET
More on CRISPR Therapeutics, Intellia Therapeutics
- Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
- These Are The Upcoming Catalysts For Crispr Therapeutics Stock
- Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- CRISPR Therapeutics GAAP EPS of -$1.28 misses by $0.02, revenue of $1.46M in-line
- Intellia Therapeutics prices $180M stock offering at discount
Read the full article on Seeking Alpha
For further details see:
Draft FDA guidance could be a boon for gene therapy developers
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
16.52% G/L:
$14.92 Last:
5,880,089 Volume:
$13.20 Open:
NTLA Latest News
June 03, 2026 12:25:00 pm
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
June 01, 2026 07:30:00 am
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
May 11, 2026 07:30:00 am
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
April 29, 2026 07:00:00 am
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
